Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2007-1-19
pubmed:abstractText
To maximize sustained virologic response (SVR) in patients with chronic hepatitis C virus (HCV) infection, treatment with pegylated interferon and ribavirin has been genotype-specific (1 vs non-1). We evaluated the effects of ribavirin and peginterferon alfa-2a dose reductions on SVR in patients infected with HCV genotype 1.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1542-7714
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
5
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
124-9
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:17196435-Adult, pubmed-meshheading:17196435-Antiviral Agents, pubmed-meshheading:17196435-Clinical Trials, Phase III as Topic, pubmed-meshheading:17196435-Dose-Response Relationship, Drug, pubmed-meshheading:17196435-Drug Therapy, Combination, pubmed-meshheading:17196435-Female, pubmed-meshheading:17196435-Genotype, pubmed-meshheading:17196435-Hepacivirus, pubmed-meshheading:17196435-Hepatitis C, Chronic, pubmed-meshheading:17196435-Humans, pubmed-meshheading:17196435-Interferon-alpha, pubmed-meshheading:17196435-Male, pubmed-meshheading:17196435-Polyethylene Glycols, pubmed-meshheading:17196435-RNA, Viral, pubmed-meshheading:17196435-Randomized Controlled Trials as Topic, pubmed-meshheading:17196435-Recombinant Proteins, pubmed-meshheading:17196435-Retrospective Studies, pubmed-meshheading:17196435-Ribavirin, pubmed-meshheading:17196435-Treatment Outcome
pubmed:year
2007
pubmed:articleTitle
Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment.
pubmed:affiliation
University of Pennsylvania, Philadelphia, Pennsylvania, USA. rajender.reddy@uphs.upenn.edu
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't